GPC3 and hepatocellular carcinoma: These findings are similar to an earlier trial investigating autologous GPC3 CAR-T cell therapy in HCC patients with induced lymphodepletion; the patients had a survival rate of 50.3% by 6 months and 42% after one year [51].